Anacor Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing small-molecule therapeutics derived from its boron chemistry platform. The company is developing AN2690, a topical antifungal product candidate for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052, a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which is licensed to GlaxoSmithKline under the companies' research and development agreement. It is also developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections; and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. The company was formerly known as AnaMax, Inc. and changed its name to Anacor Pharmaceuticals, Inc. in 2002. Anacor Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Palo Alto, California.